6-gingerol and its derivatives inhibit Helicobacter pylori-induced gastric mucosal inflammation and improve gastrin and somatostatin secretion

doi:10.3389/fmicb.2024.1451563

科研成果详情

题名	6-gingerol and its derivatives inhibit Helicobacter pylori-induced gastric mucosal inflammation and improve gastrin and somatostatin secretion
作者	Qian, Jiali 1,2; Li, Zhennan 1,3; Wang, Jinhui 4; Lin, Yuxian 1,5; Yu, Yingcong1,3,6
发表日期	2024-08-21
发表期刊	FRONTIERS IN MICROBIOLOGY 影响因子和分区
语种	英语
原始文献类型	Article
关键词	Helicobacter pylori 6-gingerol MIC gastrin somatostatin IFN-gamma IL-4 IL-8
其他关键词	T-CELLS ; INFECTION ; CONSENSUS ; DIAGNOSIS ; VIRULENCE
摘要	The resistance of Helicobacter pylori (H. pylori) has increased in recent years, prompting a trend in the research and development of new drugs. In our study, three derivatives (JF-1, JF-2, and JF-3) were synthesized using 6-gingerol as the main component, while JF-4, containing both 6-gingerol and 6-shogaol as the main components, was extracted from dried ginger. The minimum inhibitory concentrations (MICs), determined using the ratio dilution method, were 80 mu g/mL for JF-1, 40 mu g/mL for JF-2, 30 mu g/mL for JF-3, 40 mu g/mL for JF-4, 60 mu g/mL for 6-gingerol standard (SS), and 0.03 mu g/mL for amoxicillin (AMX). After treating H. pylori-infected mice, the inflammation of the gastric mucosa was suppressed. The eradication rate of H. pylori was 16.7% of JF-3 low-dose treatment (LDT), 25.0% of JF-3 high-dose treatment (HDT), 16.7% of JF-4 LDT, 16.7% of JF-4 HDT, 30% of SS LDT, 50% of SS HDT, and 36.4% of the positive control group (PCG). The levels of gastrin, somatostatin (SST), IFN-gamma, IL-4, and IL-8 were significantly recovered in the JF-3 and JF-4 administration groups, but the effect was stronger in the high-dose group. These results demonstrate that 6-gingerol and its derivatives have significant anti-Helicobacter pylori effects and are promising potential treatments for H. pylori infection.
资助项目	Wenzhou Traditional Chinese Medicine construction fund subsidy project [TD-ZY2020001]
出版者	FRONTIERS MEDIA SA
EISSN	1664-302X
卷号	15
DOI	10.3389/fmicb.2024.1451563
页数	14
WOS类目	Microbiology
WOS研究方向	Microbiology
WOS记录号	WOS:001304468300001
收录类别	SCIE
PubMed ID	39234535
通讯作者地址	[Lin, Yuxian;Yu, Yingcong]Shanghai Univ, Wenzhou Peoples Hosp, Affiliated Hosp 3, Wenzhou, Peoples R China. ; [Yu, Yingcong]Shanghai Univ, Sch Med, Shanghai, Peoples R China. ; [Lin, Yuxian]Yantai Univ, Univ Shandong,Minist Educ, Sch Pharm,Key Laboratory of Molecular Pharmacology, Collaborat Innovat Ctr Adv Drug Delivery Syst & Bi, Yantai, Peoples R China. ; [Yu, Yingcong]Wenzhou Med Univ, Clin Inst 3, Wenzhou, Peoples R China.
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/218599
专题	附属第一医院附属第一医院_麻醉科其他_温州市第三临床学院（温州市人民医院）
通讯作者	Lin, Yuxian; Yu, Yingcong
作者单位	1.Shanghai Univ, Wenzhou Peoples Hosp, Affiliated Hosp 3, Wenzhou, Peoples R China; 2.Zhejiang Univ, Dept Gastroenterol, Sir Run Run Shaw Hosp, Sch Med, Hangzhou, Zhejiang, Peoples R China; 3.Shanghai Univ, Sch Med, Shanghai, Peoples R China; 4.Wenzhou Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Wenzhou, Peoples R China; 5.Yantai Univ, Univ Shandong,Minist Educ, Sch Pharm,Key Laboratory of Molecular Pharmacology, Collaborat Innovat Ctr Adv Drug Delivery Syst & Bi, Yantai, Peoples R China; 6.Wenzhou Med Univ, Clin Inst 3, Wenzhou, Peoples R China
通讯作者单位	温州市第三临床学院（温州市人民医院）
推荐引用方式 GB/T 7714	Qian, Jiali,Li, Zhennan,Wang, Jinhui,et al. 6-gingerol and its derivatives inhibit Helicobacter pylori-induced gastric mucosal inflammation and improve gastrin and somatostatin secretion[J]. FRONTIERS IN MICROBIOLOGY,2024,15.
APA	Qian, Jiali, Li, Zhennan, Wang, Jinhui, Lin, Yuxian, & Yu, Yingcong. (2024). 6-gingerol and its derivatives inhibit Helicobacter pylori-induced gastric mucosal inflammation and improve gastrin and somatostatin secretion. FRONTIERS IN MICROBIOLOGY, 15.
MLA	Qian, Jiali,et al."6-gingerol and its derivatives inhibit Helicobacter pylori-induced gastric mucosal inflammation and improve gastrin and somatostatin secretion".FRONTIERS IN MICROBIOLOGY 15(2024).